In two independent Phase I/II dose-escalation, safety and tolerability studies of the BRD4 inhibitors INCB054329 and INCB057643 in patients with solid tumors or lymphoma, 69 and 134 patients have been recruited to INCB054329 (completed) and INCB057643 (ongoing) studies respectively [71]. The gene discussed is BRD4; the disease is lymphoma.